Bifogade filer
PDF
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Läkemedel & Handel |
Uppsala, Sweden, October 11, 2024. Dicot Pharma announces today that the US Patent and Trademark Office (USPTO) has issued a Notice of Allowance for the company's patent application No. 18/196,049 entitled "New compounds and methods of their manufacturing". The Notice of Allowance means that USPTO intends to grant a US patent once certain formal steps are completed.
Dicot Pharma AB has received a notice from the USPTO which means that one of the company's patent applications is intended to be approved in the USA after certain formal steps are completed. Once granted, the patent will be in effect until the year 2042.
The US patent application in question (No. 18/496,049) covers key steps in the manufacture of Dicot Pharma's active ingredient in the potency drug candidate LIB-01.
"We are very happy to receive the USPTO's decision which confirms our innovative edge. When granted, our new US patent will strengthen LIB-01's intellectual property protection and our position in the US market", says CEO Elin Trampe.
For further information, please contact:
Elin Trampe, CEO
Phone: +4672502 10 10
E-mail: elin.trampe@dicotpharma.com
About Dicot Pharma AB
Dicot Pharma is developing the drug candidate LIB-01, which will be a potency agent to better treat erectile dysfunction and premature ejaculation. The ambition is to create a drug with significantly longer effect and far fewer side effects, compared to current available drugs. Today, over 500 million men suffer from these sexual dysfunctions and the market is valued at USD 8 billion. Dicot's strategy is to develop LIB-01 under own auspices until phase 2a study and thereafter in partnership with larger, established pharmaceutical companies, finance and develop LIB-01 further to a registered pharmaceutical on the world market.
Dicot Pharma is listed on Spotlight Stock Market and has approximately 7,200 shareholders. For more information, please visit www.dicotpharma.com.
This disclosure contains information that Dicot Pharma AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 11-10-2024 14:15 CET.